YZR Capital’s Post

🚀 Exciting Developments in AI-Driven Healthcare! 🚀 Wow!!!! X 3 😊 Atropos Health has just announced a $33 million Series B funding round, led by Valtruis with support from strategic investors like McKesson Ventures, Cencora Ventures, Sanofi Ventures, and the Merck Global Health Innovation Fund. This significant investment is set to propel their mission of democratizing access to high-quality, personalized real-world evidence. Their cutting-edge GENEVA OS platform, powered by generative AI, is transforming clinical data into actionable insights, which is crucial for advancing value-based care. With the new funds, Atropos Health aims to expand their Evidence Network, particularly in oncology and specialty care, and fully launch ChatRWD – an AI-driven tool that dramatically reduces the time needed to produce real-world evidence. The importance of real-world evidence in enhancing patient outcomes and driving efficient healthcare solutions cannot be overstated. This milestone underscores the potential of AI in healthcare, a field that I am deeply passionate about as an AI-driven healthcare startup consultant. #AI #Digitalmedhub #Healthcare #RealWorldEvidence #ValueBasedCare #GenerativeAI #AtroposHealth

What about advancing clinical research and improving patient outcomes? 𝐋𝐚𝐬𝐭 𝐰𝐞𝐞𝐤, 𝐚𝐭 𝐭𝐡𝐞 2024 𝐃𝐈𝐀 Global Annual Meeting in San Diego, a session highlighted the transformative role of simulations and artificial intelligence. One speaker underscored the pressing need for innovation, noting, "Only 10% of drugs starting from Phase I trials reach approval; a staggering statistic that demands change." It was emphasized how leveraging technology, such as generating synthetic virtual trials, can enhance study design and predict success rates more accurately. Another speaker explored digital twins, AI-driven models that forecast clinical outcomes for trial participants. They described how these models are revolutionizing clinical trials by leveraging AI and machine learning to create personalized disease models, empowering pharmaceutical and biotech companies with predictive insights. 𝐃𝐨𝐧'𝐭 𝐦𝐢𝐬𝐬 𝐨𝐮𝐭 𝐨𝐧 𝐛𝐞𝐢𝐧𝐠 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞. The best place for us to have this chat is at 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫𝐬 𝐂𝐨𝐧𝐧𝐞𝐜𝐭, an invite-only meeting to dive deeper into these groundbreaking developments! Our scientific team initiates conversations that drive healthcare evolution. We offer exclusive discussions, access to industry leaders, and collaboration opportunities. Drop me a message for an invite to our next session. All sessions will remain invite-only. P.S. If you've read this far, we know you're motivated to make impactful changes with us. Feel free to ask me more about it! #HealthcareInnovation #ClinicalResearch #AI #DigitalTwins #HealthTech #HealthcareInnovatorsConnect #IPTLfromSingapore

Tempus AI Makes Successful Public Debut 🚀 Tempus AI, a leader in applying #artificialintelligence to healthcare, had a strong start as a publicly traded company yesterday. The medical data firm raised $410.7 million in its initial public offering, selling 23.4 million shares at $17.50 each. The shares opened at $24.25 and closed their first trading day at $27.94, up 59.7% from the IPO price, valuing the company at around $5 billion. Tempus was founded in 2015 by Eric Lefkofsky, a serial entrepreneur and co-founder of Groupon. The company has built a large library of molecular and clinical data, which it uses to develop AI-powered tools and insights to enable more personalized treatment decisions for cancer patients. With this successful IPO, Tempus is well capitalized to continue expanding its data platform, advancing its AI solutions, and partnering with healthcare providers to drive precision medicine forward.  Congratulations to the entire Tempus AI team on this milestone! The future of data-driven, AI-enabled healthcare is bright.

Unlearn Raises $50M to Transform Clinical Trials with AI-Generated Digital Twins Unlearn.AI, based in San Francisco, secures $50M Series C funding led by ALTIMETER CAPITAL MANAGEMENT LLC to revolutionize clinical trials with AI-generated digital twins. CEO Charles Fisher, Ph.D., spearheads the company's mission to eliminate trial and error in medicine by leveraging AI for highly powered TwinRCTs. Unlearn's AI models forecast health outcomes under placebo conditions, enabling faster enrollment and shorter time to market for new drugs and therapies. Qualified by the European Medicines Agency and aligned with FDA guidance, Unlearn's AI technology marks a significant advancement in integrating AI with clinical research, promising faster access to innovative treatments. #Unlearn #AI #ClinicalTrials #DigitalTwins #SanFrancisco #AltimeterCapital #CharlesFisher #TwinRCTs #Medicine #HealthOutcomes #PlaceboConditions #FasterEnrollment #TimeToMarket #EuropeanMedicinesAgency #FDA #Innovation #AIIntegration #Research #DrugDevelopment #SeriesCFunding

AZmed, a pioneering European MedTech startup, has successfully raised €15 million in Series A funding, backed by Maison Worms, Techstars, and @Tempact ventures. This investment will fuel AZmed's mission to revolutionize medical imaging with #AI, enhancing radiologists' workflows and addressing the challenges faced by healthcare professionals in managing increasing workloads and ensuring timely, accurate diagnoses. 🦴 Since earning the first-ever CE mark for its AI software for fracture detection on X-rays in 2019 and subsequent FDA clearance in 2022, AZmed has made significant strides. 🦴 Its technology is now utilized in over 1,000 healthcare facilities across 40 countries, boasting partnerships with leading institutions like the NHS and UH Cleveland Medical Center. 🦴 The software's proven effectiveness in detecting key abnormalities in X-rays and reducing report turnaround times underscores its potential to transform medical imaging. 🦴 With this funding, AZmed is set to solidify its leadership in Europe and expand globally, aiming to double its workforce and boost R&D investment. This will enable the development of new and efficient AI software for medical imaging, further advancing patient care. Julien Vidal, CEO of AZmed, highlighted the critical role of AI in meeting the growing demand for medical imaging and improving patient care pathways. This round of funding marks a significant milestone for AZmed, positioning it at the forefront of the medical imaging industry's evolution. #AZmed #SeriesAFunding #MedicalImaging #ArtificialIntelligence #HealthTech #Innovation https://azmed.co/news

ICYMI: Check out EDETEK Inc. Senior VP, Product Strategy and Development Peter Smilansky’s insightful report in a recent Clinical Research News article, “Trendspotting: What’s Coming for Clinical Trials and Research in 2024.” Peter discusses why biotech companies will increase their focus on spending on the most promising clinical trials to expedite the data readouts. He also foresees a more focused application of AI/ML technologies for clinical research and development. Read more at https://lnkd.in/d2GFrEZS. Jian Chen, Michele Cherry, Kevin Prizeman, Craig Lipset, John F. Kouten, Michael W. Young, Cambridge Healthtech Institute #ClinicalTrials #ClinicalResearch #ClinicalOperations  #clinicaldata  #digitaldata  #clinicaldevelopment #datamanagement

AI investment, by the numbers:  • U.S. digital health startups with AI/ML-enabled solutions raised more than $18B in venture funding across 2021-2023 • In that time period, the top value propositions for AI investment were research & development, clinical decision support tools, and diagnostic tools • Top therapeutic areas for AI digital health startup investment in 2021-2023 were oncology, cardiovascular care, and mental health With all of the buzz and possibility, it can be difficult to make sense of the concrete ways AI can drive true operational efficiency and innovation at your organization. For pharma leaders looking for practical tips on how to harness AI’s capabilities, join Rock Health Advisory on June 11 at 9am PT / 12pm ET for an informative conversation featuring:  • Junaid Bajwa: Chief Medical Scientist, Microsoft • Ashita Batavia, MD, MS: Head of Hematology & Oncology Data Sciences, R&D Johnson & Johnson Innovative Medicine • Lana Feng, Ph.D.: Co-founder & CEO, Huma.AI • Moderated by Sari Kaganoff: Chief Commercial Officer, Rock Health Advisory Register to attend here: https://lnkd.in/ebCudBJx #AIinPharma #DigitalHealth #LifeSciencesInnovation 

Clinical trials are notoriously slow and expensive. Our latest market map highlights 96 tech companies transforming this process, making trials faster, cheaper, and more patient-centric. Decentralized clinical trials (DCTs) are gaining major traction. AstraZeneca’s $80M investment in Huma and the acquisitions of Science 37 and Emvenio Research signal a wave of consolidation. Digital twins and AI-driven analytics are also emerging as game changers—enabling faster, more efficient trials and improving patient recruitment. Explore the full report to see how clinical trials tech is reshaping the industry (link in comments, accessible for CB Insights clients, but reach out to discuss!) #ClinicalTrials #HealthcareInnovation #DigitalHealth #AI #PatientCentricity #ClinicalResearch

🚀 This week, let's dive into eOS - an innovative platform transforming the way clinical trials are managed. Founded by the tech-savvy and visionary Andrzej Kurek, eOS is the answer to the pressing need for streamlined, efficient data management in clinical research. 📊 Offering a low-code, AI-integrated platform, eOS stands out for its adaptability and user-centric approach. It's designed to connect patients, sponsors, CRO companies, and research centers in a seamless ecosystem for clinical trial management. 🔬 Watching eOS's progression is a window into the future of healthcare, where technology enhances human care and efficiency in clinical research. 💼 HealthTech of the Week is a series spotlighting the most innovative startups and medical projects. Supported by NIL IN - Sieć Lekarzy Innowatorów. Read about eOS and other interesting HealthTech projects on my blog page. Link below. 🔽 #HealthTech #eOS #ClinicalTrials #AI #HealthTechofTheWeek

Transforming Clinical Trials with AI: DST Technology’s Game Changer Pawan Agrawal On this International Clinical Trial Day, let's envision a future where innovation and efficiency revolutionize drug development. DST Technology's AI Accelerator stands at the forefront of this transformation, propelling preclinical and clinical workups into a new era of precision, speed, and cost-effectiveness. Imagine reducing the time and cost of clinical trials by leveraging the power of artificial intelligence. Our AI Accelerator optimizes data analysis, enhances patient recruitment, and streamlines regulatory compliance, ensuring faster, more accurate results. For Contract Research Organizations (CROs), this means unparalleled efficiency and a competitive edge in a rapidly evolving landscape. Consider the case of a leading CRO that integrated our AI solutions into their clinical trial process. By automating data management and predictive modeling, they achieved a 30% reduction in trial timelines and a 25% cost saving, ultimately accelerating the delivery of life-saving treatments to patients. Join us in celebrating innovation. Embrace the future of clinical trials with DST Technology's AI Accelerator—because every moment saved is a step closer to a healthier world. #InternationalClinicalTrialDay #AIinClinicalTrials #DSTTechnology #PharmaInnovation #CROefficiency